No Data
No Data
Tigermed Schedules EGM for Major Corporate Updates
Contract research organizations are generally declining. Wuxi Apptec (02359) fell 9.74%. The uncertainty of the Biosecurity Law Bill weakened investor confidence.
Jinwu Finance News | The concept of contract research organizations is generally trending downward. Wuxi Apptec (02359) fell 9.74%, Frontage (01521) fell 5.36%, Tigermed (03347) fell 4.57%, Wuxi Bio (02269) fell 3.7%, and Pharmaron (03759) fell 3.13%. Citigroup has released a report stating that the U.S. House of Representatives has passed the Biosecurity Bill, but it is currently unknown whether the Senate will adopt the House version of the bill, or consider another version, or even incorporate the Biosecurity Bill into a larger comprehensive bill. Nevertheless, Citigroup believes that
HK stocks fluctuate | CRO concept stocks plummeted in early trading. The U.S. House of Representatives has passed the draft of the Biosecurity Law, and related companies have quickly issued clarification announcements.
CRO concept stocks tumbled in the morning session, as of the time of publication, wuxi apptec (02359) fell by 9.74%, closing at HK$32.45; frontage (01521) fell by 10.71%, closing at HK$0.5; pharmaron (03759) fell by 4.31%, closing at HK$8.87; tigermed (03347) fell by 3.66%, closing at HK$26.35.
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Tigermed (03347.HK) suffered a shareholding reduction of 1.023 million shares by E Fund Fund.
According to the latest equity disclosure information from the Stock Exchange, on August 29, 2024, tigermed (03347.HK) was sold by China Asset Management Co., Ltd. on the exchange at an average price of 29.4372 Hong Kong dollars per share, reducing its shareholding by 1.023 million shares, involving approximately 30.1143 million Hong Kong dollars. After the reduction, the latest number of shares held by China Asset Management Co., Ltd. is 10,764,309 shares, and the shareholding ratio has decreased from 9.57% to 8.74%.
Tigermed (300347.SZ): Cumulatively repurchased 0.4226% of shares.
On September 4th, Tigermed (300347.SZ) announced that as of August 31, 2024, the company's share repurchase special securities account has repurchased a total of 3,655,200 shares of the company through centralized bidding trading, accounting for 0.4226% of the total share capital of the company, and accounting for 0.4927% of the total A-share capital of the company. The highest fill price was 55.30 yuan/share, and the lowest fill price was 48.17 yuan/share, with a total transaction amount of 191,146,104.89 yuan (excluding transaction fees).
No Data
No Data